Skip to Content

Join the 'Xeomin' group to help and get support from people like you.

Xeomin News

Merz North America Announces FDA Approval of Xeomin (incobotulinumtoxinA) for Treatment of Adult Upper Limb Spasticity

Posted 30 Dec 2015 by Drugs.com

RALEIGH, N.C.- December 23, 2015 --Merz North America, U.S. affiliate of the global Merz Pharma Group, announces that Xeomin (incobotulinumtoxinA) has received U.S. FDA approval for the treatment of upper limb spasticity (ULS) in adult patients. In clinical studies, treatment with Xeomin (incobotulinumtoxinA) for adult ULS resulted in statistically and clinically significant improvements in muscle tone, with a safety profile similar to that observed for other Xeomin (incobotulinumtoxinA) indications. “We know that each patient has unique needs, and this new indication for Xeomin (incobotulinumtoxinA) is a result of our long-term commitment to serving individuals living with movement disorders and spasticity,“ said Glenn Block, Vice President and Head – US Neurosciences for Merz North America. “We look forward to supporting the launch of Xeomin for adult upper-limb spasticity with forwar ... Read more

Related support groups: Upper Limb Spasticity, Xeomin, Incobotulinumtoxina

Medication Errors Occur Every 8 Minutes in U.S. Children

Posted 20 Oct 2014 by Drugs.com

MONDAY, Oct. 20, 2014 – A child receives the wrong medication or the wrong dosage every eight minutes in the United States, according to a recent study. Nearly 700,000 children under 6 years old experienced an out-of-hospital medication error between 2002 and 2012. Out of those episodes, one out of four children was under a year old. As the age of children decreased, the likelihood of an error increased, the study found. Though 94 percent of the mistakes didn't require medical treatment, the errors led to 25 deaths and about 1,900 critical care admissions, according to the study. "Even the most conscientious parents make errors," said lead author Dr. Huiyun Xiang, director of the Center for Pediatric Trauma Research at Nationwide Children's Hospital in Columbus, Ohio. That conscientiousness may even lead to one of the most common errors: Just over a quarter of these mistakes involved a ... Read more

Related support groups: Xanax, Klonopin, Clonazepam, Seroquel, Ativan, Valium, Abilify, Soma, Lorazepam, Alprazolam, Azithromycin, Diazepam, Benadryl, Flexeril, Latuda, Zyprexa, Risperdal, Risperidone, Cyclobenzaprine, Baclofen

Accidental Medication Poisonings in Kids on the Rise

Posted 16 Sep 2011 by Drugs.com

FRIDAY, Sept. 16 – Despite ongoing prevention efforts, a growing number of young children are being accidentally poisoned with medications, according to new research. The study, which was based on data reported to the American Association of Poison Control Centers between 2001 and 2008, found that medication poisoning among children aged 5 and under increased by 22 percent, although the number of children in the United States in this age group rose by only 8 percent during the study period. "The problem of pediatric poisoning in the U.S. is getting worse, not better," Dr. Randall Bond, of Cincinnati Children's Hospital Medical Center, said in a hospital news release. In conducting the study, which is scheduled for publication in the Journal of Pediatrics, the researchers reviewed information on over 544,000 children who landed in the emergency department due to medication poisoning ... Read more

Related support groups: Xanax, Suboxone, Oxycodone, Hydrocodone, Methadone, Percocet, OxyContin, Klonopin, Vicodin, Lisinopril, Norco, Fentanyl, Clonazepam, Morphine, Ativan, Ambien, Valium, Metoprolol, Codeine, Lortab

Merz Aesthetics Announces FDA Approval Of Xeomin (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients

Posted 21 Jul 2011 by Drugs.com

SAN MATEO, Calif., July 21, 2011 /PRNewswire/ – Merz Aesthetics today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients. "The FDA approval of Xeomin is a significant milestone for Merz Aesthetics and a promising addition to our entire aesthetics franchise," said Dennis Condon, President and Chief Business Officer of Merz Aesthetics, Inc. "We are confident that Xeomin will provide patients and physicians with a new option for improving the appearance of glabellar lines." "Xeomin is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the Phase III clinical trials," said Derek H. Jones, M.D., an investigator for the Xeomin U.S. ... Read more

Related support groups: Xeomin, Incobotulinumtoxina, Glabellar Lines

Ask a Question

Further Information

Related Condition Support Groups

Facial Wrinkles, Cervical Dystonia, Blepharospasm, Upper Limb Spasticity

Xeomin Patient Information at Drugs.com